|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2009-2-2
|
|
pubmed:abstractText |
Chemoimmunotherapy combining fludarabine, cyclophosphamide, and rituximab (FCR) is an active regimen for untreated patients with chronic lymphocytic leukemia (CLL) with 70% complete responses (CRs) and 95% overall responses (ORs). However, grade 3/4 neutropenia was reported in 52% of cycles of treatment. The purpose of this trial was to maintain the high responses but reduce the toxicity of FCR by decreasing the fludarabine and cyclophosphamide (FCR-Lite).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Alkylating,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Vidarabine,
http://linkedlifedata.com/resource/pubmed/chemical/fludarabine,
http://linkedlifedata.com/resource/pubmed/chemical/rituximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:BoyiadzisMichaelM,
pubmed-author:ButchkoAllysonA,
pubmed-author:FoonKenneth AKA,
pubmed-author:LamanAndrewA,
pubmed-author:LandStephanie RSR,
pubmed-author:LenzerDianaD,
pubmed-author:MarksStanleyS,
pubmed-author:MeisnerDennisD,
pubmed-author:PietragalloLouisL,
pubmed-author:RaptisAnastasiosA,
pubmed-author:SchaeferPatriciaP,
pubmed-author:SuleckiMathewM,
pubmed-author:TarhiniAhmadA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
498-503
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19075274-Adult,
pubmed-meshheading:19075274-Aged,
pubmed-meshheading:19075274-Antibodies, Monoclonal,
pubmed-meshheading:19075274-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:19075274-Antineoplastic Agents,
pubmed-meshheading:19075274-Antineoplastic Agents, Alkylating,
pubmed-meshheading:19075274-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19075274-Cyclophosphamide,
pubmed-meshheading:19075274-Drug Therapy, Combination,
pubmed-meshheading:19075274-Female,
pubmed-meshheading:19075274-Humans,
pubmed-meshheading:19075274-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:19075274-Male,
pubmed-meshheading:19075274-Middle Aged,
pubmed-meshheading:19075274-Neutropenia,
pubmed-meshheading:19075274-Treatment Outcome,
pubmed-meshheading:19075274-Vidarabine
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
|
|
pubmed:affiliation |
Department of Medicine and Biostatistics, University of Pittsburgh School of Medicine, Graduate School of Public Health, University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center Cancer Centers, PA, USA. kfoon@nvcancer.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
